Recently, obeticholic acid (OCA), a novel FXR agonist, preliminarily exhibits a tumor inhibitory activity in CRC [12], hepatocellular carcinoma (HCC) [13], and cholangiocarcinoma [14]. This evidence concerns the gene NR1H4 and neoplasm.